Clinical Trials Logo
  1. Home
  2. Human Influenza
  3. NCT02600585
  4. Details
NCT02600585 Clinical Trial

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Human Influenza Clinical Trial

Official title:
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults 18 Years of Age and Older

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02600585
Other study ID # PSC13
Secondary ID
Status Completed
Phase N/A
First received November 5, 2015
Last updated October 11, 2017
Start date November 2015
Est. completion date September 2016

Study information
Verified date October 2017
Source Protein Sciences Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of this study is to retrospectively characterize the safety of Flublok in adults 18 years of age and older, in comparison with egg-based trivalent or quadrivalent inactivated influenza vaccines (IIVs), using a methodological approach designed to query the database of electronic health records (EHR) maintained by Kaiser-Permanente, Northern California (KPNC), a large medical care organization (MCO).

Description:

The primary analysis is a nonrandomized, observational retrospective cohort study. Data on adults 18 years of age and older who were enrolled in the KPNC database during the risk intervals after vaccination analyzed for this study who were vaccinated with Flublok or an IIV (either IIV3 or IIV4) will be identified for analysis. The rates of occurrence of specific MAEs of interest in pre-specified risk intervals following Flublok and IIV will be compared.

Recruitment information / eligibility
Status Completed
Enrollment 254648
Est. completion date September 2016
Est. primary completion date September 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Data from the EHR of all adult KPNC members 18 years of age and older, who received Flublok for active immunization against influenza as part of routine medical care within the KPNC system. The comparator cohort will include data from all adults in the same age group who received any IIV (trivalent or quadrivalent) during the period of Flublok administration.

Exclusion Criteria:

Healthcare providers are expected not to administer Flublok or IIV to individuals with known contraindication to either vaccine (see product package inserts). However, there will be no exclusions other than age and KPNC membership criteria at the time of vaccination.

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Recombinant Influenza Vaccine
Intramuscular injection of study vaccine
• Inactivated Influenza Vaccine
Intramuscular injection of study vaccine

Locations
Country Name City State
United States Kaiser Permanente Vaccine Study Center Oakland California

Sponsors (2)
Lead Sponsor Collaborator
Protein Sciences Corporation Kaiser Permanente

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of Participants with Serious adverse events (SAEs) and medically-attended adverse events (MAEs) Incidence of Serious and/or Medically-Attended Adverse events Five months post-vaccination
See also
  Status Clinical Trial Phase
Terminated NCT01690637 - Panama and El Salvador Children's Oseltamivir Study Phase 4
Completed NCT03572491 - Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine Phase 3
Recruiting NCT04487041 - Tfh Dysfunction in HIV and Aging Phase 4
Completed NCT02387294 - Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents Phase 3
Completed NCT02398097 - Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects Phase 4
Completed NCT01511744 - Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine Phase 4
Completed NCT01342796 - Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Phase 2
Completed NCT01677702 - Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization N/A
Active, not recruiting NCT01096225 - Immunogenicity Study of S-OIV H1N1 Influenza Vaccine N/A
Completed NCT00880659 - Bangladesh Secondary Transmission Handwashing Protocol Phase 2
Completed NCT01879553 - Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above Phase 2
Completed NCT01879540 - Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age Phase 2
Completed NCT01636102 - Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above Phase 2
Completed NCT01651104 - Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects Phase 2
Completed NCT03448705 - Safety of 4Fluart ID Suspension for Injection in Adult Subjects Phase 1
Completed NCT02478905 - Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting N/A
Recruiting NCT04431050 - Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
Completed NCT01568788 - Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine N/A
Completed NCT05155319 - Universal Influenza A Vaccine in Healthy Adults Phase 1
Completed NCT01885117 - Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above Phase 3